Aurinia Pharmaceuticals Inc.
AUPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.08 | 0.57 | 0.12 | -0.27 |
| FCF Yield | 3.43% | -2.65% | -13.02% | -5.38% |
| EV / EBITDA | 40.36 | -21.20 | -5.08 | -15.42 |
| Quality | ||||
| ROIC | -0.77% | -18.98% | -26.64% | -36.03% |
| Gross Margin | 87.99% | 91.94% | 95.77% | 97.61% |
| Cash Conversion Ratio | 7.72 | 0.43 | 0.74 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | 20.61% | 56.71% | 38.80% | 423.43% |
| Free Cash Flow Growth | 229.05% | 57.18% | 49.86% | -106.21% |
| Safety | ||||
| Net Debt / EBITDA | -0.13 | -0.77 | 0.83 | 1.26 |
| Interest Coverage | -0.97 | -33.04 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.72 | 0.36 | 0.23 | 0.06 |
| Cash Conversion Cycle | 496.58 | 962.80 | 1,432.86 | 5,291.24 |